Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase I trial studies the side effects and best dose of retinoid 9cUAB30 in preventing cancer in healthy volunteers. The use of retinoid 9cUAB30 may keep cancer from forming in healthy volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the toxicities and recommended phase II dose of 9cUAB30 (retinoid 9cUAB30).

II. To characterize the urine and plasma single dose and steady state pharmacokinetics of 9cUAB30 in normal volunteers.

SECONDARY OBJECTIVES:

I. To correlate the pharmacokinetics of 9cUAB30 with toxicity. II. To compare observed toxicity between placebo controls and each dose level. III. To assess for any change in single dose pharmacokinetics (PK) after repeat dosing (day 1 vs. day 36).

OUTLINE: This is a dose-escalation study. Participants are randomized to 1 of 2 treatment arms.

ARM I: Participants receive retinoid 9cUAB30 orally (PO) once daily (QD) on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.

ARM II: Participants receive a placebo PO QD on days 1 and 8-36.

After completion of study treatment, patients are followed up at 7 and 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subject

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (retinoid 9cUAB30)

Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.

Group Type EXPERIMENTAL

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Pharmacological Study

Intervention Type OTHER

Correlative studies

Retinoid 9cUAB30

Intervention Type DRUG

Given PO

Arm II (placebo)

Participants receive a placebo PO QD on days 1 and 8-36.

Group Type PLACEBO_COMPARATOR

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Pharmacological Study

Intervention Type OTHER

Correlative studies

Placebo

Intervention Type OTHER

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Pharmacological Study

Correlative studies

Intervention Type OTHER

Placebo

Given PO

Intervention Type OTHER

Retinoid 9cUAB30

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

placebo therapy PLCB sham therapy 9cUAB30

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal volunteers, either male or female
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 or Karnofsky \>= 70%
* White blood cell (WBC) \>= 3000/mm\^3
* Platelets \>= 100,000/mm\^3
* Hemoglobin \> 10 g/dL
* Bilirubin =\< upper limit of institutional normal
* Aspartate aminotransferase (AST) =\< upper limit of institutional normal
* Creatinine within institutional normal limits
* Sodium, potassium, chloride, bicarbonate: all =\< upper limit of institutional normal
* Fasting triglycerides =\< 1.5 x upper limit of normal (ULN)
* Fasting cholesterol =\< 1.5 x ULN
* Participants must agree to discontinue all vitamin supplements while taking study medication and for thirty days past the last dose of study medication
* Heterosexual women and men must agree to use TWO effective forms of birth control for the duration of study participation and for 30 days following the last dose of study medication

* Men must agree not to donate sperm during the study and for three months after receiving the last dose of study drug
* The following persons are not considered to be able to father or bear children and therefore are eligible to participate without the use of concurrent birth control:

* Female with bilateral oophorectomy and/or hysterectomy
* Female with fallopian tubes cut, tied, or sealed
* Female with sterilization implant (e.g. Adiana, Essure) placed \> 3 months prior to randomization
* Female post-menopausal (\> 1 year since last menses)
* Male with vasectomy \> 3 months prior to randomization
* One of the following methods of birth control must be used by women of childbearing potential:

* Combined oral contraceptive pill in continuous use for \> 30 days prior to study entry
* Vaginal ring (e.g. NuvaRing) in continuous use for \> 30 days prior to study entry
* Skin patch (e.g. Ortho Evra) in continuous use for \> 30 days prior to study entry
* Injection (e.g. Depo-Provera, Noristerat) in continuous use for \> 30 days prior to study entry
* Copper intrauterine device (IUD) (e.g. ParaGard)
* Note: The following hormonal methods are NOT acceptable:

* Low dose progesterone only oral contraceptive pill ("mini pills" e.g. Micronor, Nor-Q.D., Ovrette)
* Norplant subdermal implant
* Mirena Hormonal Implanted Uterine Device (IUD)
* In addition to the above method of contraception, one of the following methods of contraception will ALSO be used for the duration of study participation and for 30 days following the last dose of study medication:

* Diaphragm, cervical cap, or cervical shield with spermicide
* Contraceptive sponge (e.g. Today Sponge)
* Condom (male or female type) plus spermicide
* Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug
* Participants must have the ability to understand, and the willingness to sign, a written informed consent document

Exclusion Criteria

* Participants may not be taking medications that might interact with 9cUAB30
* Participants may not be taking lipid lowering agents
* Participants may not receive any other investigational agents within 30 days of enrollment nor during study participation
* Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
* Participants with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30
* Individuals known to be human immunodeficiency virus (HIV)-positive may not participate in this study
* Individuals with a history of cancer diagnosis or reoccurrence \< 5 years from study entry may not participate; however, individuals with a history of squamous or basal cell carcinoma of the skin \< 5 years from study entry will not be excluded from this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jill Kolesar

Role: PRINCIPAL_INVESTIGATOR

University of Wisconsin Chemoprevention Consortium

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Site Status

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, United States

Site Status

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States